OOIR: Observatory of International Research

Papers

(The H4-Index of Leukemia & Lymphoma is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy	57
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome	34
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	33
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and ‘bridge’ to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma	31
Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia	30
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	30
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma	28
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	24
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a	24
Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia	22
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated bod	22
Polatuzumab vedotin extravasation injury: a case report	22
Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutat	21
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?	20
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	20
Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center	19
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim ¹⁸ F-FDG PET/CT scans	19
Efficacy of lenalidomide in a patient with systemic mastocytosis associated withSF3B1-mutant myelodysplastic syndrome	18